

Development of Universal Influenza Vaccine: Challenges, Advances, and Future Prospects

Dr. Kavita Joshi

Associate Professor

Department of Microbiology

Postgraduate Institute of Medical Education and Research (PGIMER)

Chandigarh, India

Email: kavita.joshi91@gmail.com

Dr. Arvind Rao

Research Scientist

Department of Virology

Indian Council of Medical Research (ICMR), New Delhi, India

Email: arvind.rao89@yahoo.in

Abstract

Seasonal influenza poses a persistent global health challenge, with annual epidemics causing significant morbidity and mortality. The rapid antigenic drift and shift in influenza viruses necessitate frequent vaccine reformulation, limiting the effectiveness of conventional vaccines. Development of a universal influenza vaccine (UIV) aims to elicit broad, long-lasting protection against diverse influenza strains. This review examines the immunological targets, including conserved hemagglutinin stalk, matrix proteins, and internal antigens, alongside current vaccine platforms such as mRNA, viral vectors, and nanoparticle-based approaches. Key challenges, including antigenic variability, immune imprinting, and vaccine delivery, are discussed. Recent preclinical and clinical advances demonstrate the feasibility of UIV candidates, highlighting their potential to transform influenza prevention strategies. Future perspectives emphasize integration of novel adjuvants, structural vaccinology, and immunogen design to achieve broad-spectrum, durable immunity.

Keywords: *Universal influenza vaccine, hemagglutinin stalk, conserved antigens, vaccine platforms, immunogenicity, viral variability, structural vaccinology.*

INTRODUCTION

Influenza viruses remain a major cause of respiratory disease globally, resulting in 290,000–650,000 deaths annually. The primary challenge in influenza vaccination arises from the high mutation rate of hemagglutinin (HA) and neuraminidase (NA) glycoproteins, leading to antigenic drift and occasional antigenic shift. Seasonal vaccines often have suboptimal efficacy due to strain mismatches. A universal influenza vaccine (UIV) aims to overcome these limitations by targeting conserved viral epitopes to induce broad and durable immunity. This paper reviews the mechanisms, challenges, advances, and future directions in UIV development.

IMMUNOLOGICAL TARGETS FOR UNIVERSAL INFLUENZA VACCINES

1. **Conserved Hemagglutinin (HA) Stalk Domain:** Unlike the variable HA head, the stalk domain is relatively conserved and can induce broadly neutralizing antibodies (bnAbs).
2. **Matrix Proteins (M1, M2e):** M2 ectodomain is highly conserved and capable of eliciting protective humoral responses.
3. **Internal Antigens (NP, PB1):** Induce cytotoxic T lymphocyte (CTL) responses contributing to cross-protection.

VACCINE PLATFORMS AND APPROACHES

1. **MRNA Vaccines:** Encode conserved antigens, capable of rapid production and inducing both humoral and cellular immunity.
2. **Viral Vector-Based Vaccines:** Use adenovirus or vaccinia vectors to deliver conserved antigens, stimulating robust immune responses.
3. **Nanoparticle-Based Vaccines:** Present multiple copies of antigens in a repetitive array, enhancing immunogenicity and cross-reactivity.
4. **Peptide and Epitope-Based Vaccines:** Focus on conserved epitopes to elicit bnAbs or CTL responses.

Table 1: Immunological Targets and Vaccine Platforms for Universal Influenza Vaccine

Target Antigen	Vaccine Platform	Immune Response Induced	Clinical Status
HA Stalk Domain	mRNA, Viral vector, Nanoparticle	Broad neutralizing antibodies	Phase I/II trials
M2 Ectodomain (M2e)	Peptide, VLP, Nanoparticle	Antibody-mediated viral clearance	Preclinical/Phase I
Internal Antigens (NP, PB1)	Viral vector, mRNA	Cytotoxic T-cell response	Phase I/II trials

Table 1 summarizes the main antigenic targets, corresponding vaccine platforms, type of immune response induced, and clinical status of UIV candidates.

CHALLENGES IN UNIVERSAL INFLUENZA VACCINE DEVELOPMENT

1. **Antigenic Variability:** High mutation rates in influenza virus necessitate targeting conserved regions while maintaining immunogenicity.
2. **Immune Imprinting (Original Antigenic Sin):** Pre-existing immunity may bias immune responses towards prior strains, reducing vaccine efficacy.
3. **Suboptimal Immune Response:** Conserved antigens may be less immunogenic than variable HA head regions.
4. **Vaccine Delivery and Stability:** Ensuring appropriate antigen presentation and long-term stability poses formulation challenges.

ADVANCES AND RECENT PROGRESS

Recent studies demonstrate promising UIV candidates:

1. **Chimeric HA Vaccines:** Sequential immunization with chimeric HAs exposes conserved stalk domains, eliciting bnAbs.
2. **MRNA-Based Platforms:** Rapid design and scalable production enable targeting of conserved antigens; early trials show robust antibody and T-cell responses.

3. **Viral Vector Vaccines:** Adenoviral or modified vaccinia Ankara vectors expressing NP and M1 proteins induce cross-reactive CTL responses.
4. **Nanoparticle Vaccines:** Ferritin-based nanoparticles presenting HA stalk or M2e epitopes enhance immunogenicity and cross-protection in preclinical models.

Table 2: Examples of Universal Influenza Vaccine Candidates and Their Progress

Vaccine Candidate	Platform	Target Antigen	Stage of Development
Chimeric HA (cHA)	Protein/Adjuvant	HA stalk	Phase I/II clinical trials
mRNA-HA-Stalk	mRNA	HA stalk	Preclinical/Phase I
M2e-Nanoparticle	Nanoparticle	M2e	Preclinical
NP/M1 Adenoviral Vector	Viral vector	NP, M1	Phase I clinical trial

Table 2 provides examples of UIV candidates, their platforms, target antigens, and stage of development.

FUTURE PERSPECTIVES

Future strategies to enhance UIV efficacy include:

1. **Structural Vaccinology:** Rational design of antigens using structural biology to expose conserved epitopes effectively.
2. **Novel Adjuvants:** Incorporation of TLR agonists or saponin-based adjuvants to boost immune responses.
3. **Combination Approaches:** Utilizing multiple antigens or platforms to elicit both humoral and cellular immunity.
4. **Personalized Vaccination:** Consideration of individual immunological history to optimize response to UIVs.

CONCLUSION

The development of a universal influenza vaccine represents a critical advancement in global public health by providing broad, durable protection against diverse influenza strains. Targeting conserved antigens such as HA stalk, M2e, and internal proteins through innovative platforms including mRNA, viral vectors, and nanoparticles has demonstrated promising

preclinical and early clinical results. Challenges including antigenic variability, immune imprinting, and optimal immune response must be addressed through rational vaccine design, adjuvant optimization, and strategic immunization regimens. Integration of structural vaccinology, novel adjuvants, and personalized approaches will accelerate the development of effective UIVs, ultimately reducing seasonal influenza burden and improving pandemic preparedness.

REFERENCES

1. Krammer, F., et al. (2018). Influenza. *Nat Rev Dis Primers*, 4, 3.
2. Erbeling, E.J., et al. (2018). A universal influenza vaccine: the strategic plan for the U.S. National Institute of Allergy and Infectious Diseases. *J Infect Dis*, 218(3), 347–354.
3. Nachbagauer, R., et al. (2016). Universal influenza virus vaccines and therapeutic antibodies. *Clin Microbiol Infect*, 22, S103–S113.
4. Yassine, H.M., et al. (2015). Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. *Nat Med*, 21, 1065–1070.
5. Pardi, N., et al. (2018). mRNA vaccines — a new era in vaccinology. *Nat Rev Drug Discov*, 17, 261–279.
6. Impagliazzo, A., et al. (2015). A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. *Science*, 349, 1301–1306.
7. Nachbagauer, R., & Krammer, F. (2017). Universal influenza virus vaccines and therapeutic antibodies. *Clin Microbiol Infect*, 23, 222–228.
8. Paules, C., et al. (2018). The global challenge of influenza. *N Engl J Med*, 378, 7–10.